Welcome to our dedicated page for Dr Reddys Labs SEC filings (Ticker: RDY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Dr. Reddy's Laboratories Limited (RDY) SEC filings page on Stock Titan brings together the company’s U.S. regulatory disclosures as a foreign private issuer listed on the New York Stock Exchange. Dr. Reddy's files reports such as Form 6-K with the Securities and Exchange Commission, providing investors with access to financial results, board and corporate actions, and other information furnished under its home-country requirements.
Key filing types for Dr. Reddy's include periodic Form 6-K submissions that often attach consolidated IFRS financial statements, segment data for Global Generics and Pharmaceutical Services and Active Ingredients (PSAI), and management commentary on revenue trends, R&D spending and regional performance. These filings can also include intimations regarding board meetings, corporate actions and other material updates first disclosed in India.
For a pharmaceutical manufacturer active in APIs, generics, branded generics, biosimilars and OTC products, SEC filings are a primary source for understanding segment performance, geographic mix and investment in R&D. Investors can use them to track how Dr. Reddy's generics and biosimilars portfolios evolve, how collaborations and acquisitions contribute to results, and how the company allocates capital across regions and product categories.
On Stock Titan, each new RDY filing from EDGAR is captured and organized chronologically. AI-powered summaries help explain the main points of lengthy documents, highlighting items such as revenue movements, margin changes, R&D focus areas and notable regulatory or ESG disclosures. Users can quickly scan these summaries before diving into the full text of a 6-K or related exhibits.
In addition to financial information, this page can surface filings that relate to governance, risk and compliance, complementing press releases about inspections, recalls or ESG recognitions. Together, these documents provide a structured view of Dr. Reddy's regulatory footprint in the U.S. and support deeper analysis of the RDY stock for research-oriented investors.
Dr. Reddy’s Laboratories Limited reports that the U.S. Department of Justice has closed its inquiry into alleged improper payments to healthcare professionals under the Foreign Corrupt Practices Act and has not recommended any enforcement action against the company. This follows an earlier letter from the U.S. Securities and Exchange Commission stating it had concluded a related investigation and did not intend to recommend enforcement. These outcomes relate to an anonymous complaint first disclosed in 2020 and formally notified to U.S. and Indian regulators, and they remove the risk of FCPA enforcement actions based on the investigated matters.
Dr. Reddy’s Laboratories Limited reports the outcome of a United States Food & Drug Administration inspection at its formulations manufacturing facility FTO-SEZ PU01 in Srikakulam, Andhra Pradesh. The company has received the Establishment Inspection Report on March 4, 2026.
The USFDA classified the inspection outcome as “Voluntary Action Indicated (VAI)” and stated that the inspection is officially closed under 21 CFR 20.64(d)(3). This update follows an earlier intimation dated December 12, 2025 about the same GMP and Pre-Approval Inspection.
Dr. Reddy’s Laboratories Limited filed a Form 6-K to share its upcoming schedule of analyst and institutional investor meetings. The company’s management plans to participate in two group meetings with investors in early March 2026.
On March 4, 2026, management will attend an in-person group meet organized by Ambit Capital in Hyderabad from 11:00 to 13:30 IST. On March 5, 2026, they will join a virtual group meet organized by Goldman Sachs from 11:15 to 12:15 IST. The company notes that this schedule may change due to any exigencies on the part of investors or the company.
Dr. Reddy’s Laboratories Limited reports that the U.S. Securities and Exchange Commission has concluded its investigation into earlier anonymous allegations of improper payments to healthcare professionals in Ukraine and other markets. The SEC’s letter dated February 23, 2026 states it does not intend to recommend any enforcement action against the company at this time.
The company notes that the SEC’s communication, issued under Securities Act Release No. 5310, should not be read as an exoneration or a guarantee that no action will ever result, but it does indicate that the current investigation is being closed without an enforcement recommendation.
Dr. Reddy’s Laboratories has agreed to acquire the Indian trademarks and related assets of hormone replacement therapy brands Progynova® and Cyclo‑Progynova® from Mercury Pharma Group Limited for USD 32.15 million.
Progynova®, an estradiol valerate therapy, is described as the #1 brand in the estradiol represented pharmaceutical market in India and recorded sales of INR 100 crore as per IQVIA MAT December 2025. Cyclo‑Progynova® combines estradiol valerate and norgestrel for estrogen deficiency symptoms treatment.
The deal is not a related‑party transaction and is intended to strengthen Dr. Reddy’s gynecology portfolio in India and mark a strategic entry into the hormone replacement therapy segment.
Dr. Reddy’s Laboratories Limited has allotted 12,665 equity shares of Re.1 each on February 17, 2026 to eligible employees following the exercise of stock options. These options were granted under the Dr. Reddy’s Employees Stock Options Scheme, 2002 and the Employees ADR Stock Option Scheme, 2007.
The shares were exercised at prices ranging from Re.1 to Rs. 735.80 per share, and the new shares rank pari passu with existing equity shares. After this allotment, total issued shares are 83,46,44,020 and total issued share capital is Rs. 83,46,44,020, with paid-up capital of 83,46,43,020 equity shares of Re.1 each.
Dr. Reddy’s Laboratories Limited has notified exchanges that its management will participate in an investor conference organized by Kotak Institutional Equities. The meetings are scheduled in Mumbai on 23 February 2026, will be held in person, and structured as group meets from 09:00 to 17:00 IST. The company notes the schedule may change if required by either the investors or the company.
Dr. Reddy’s Laboratories Limited has filed a Form 6-K to report that Mr. Sushrut Kulkarni, Global Head of IPDO and Senior Management Personnel, has resigned. He will cease employment and senior management responsibilities effective from the close of business on May 8, 2026, as he plans to explore opportunities outside the company.
The company states that the disclosure is made under Regulation 30 of the SEBI Listing Regulations, with required details provided in an annexure. In his resignation letter, Mr. Kulkarni undertakes to support the company during his notice period and ensure a smooth handover of responsibilities.
Dr. Reddy’s Laboratories Limited filed a Form 6-K to share its schedule for an upcoming investor interaction. The company’s management plans to participate in a Nuvama-organized investor conference in Mumbai on 9 February 2026, holding in-person group meetings from 09:00 to 17:00 IST. The company notes that this schedule may change if required by either the investors or the company.
Dr. Reddy’s Laboratories reported Q3 FY26 results showing modest overall growth but pressure on earnings. Revenue grew 4.4%, driven by double-digit gains in base businesses excluding Lenalidomide and supported by favourable foreign exchange.
Reported EBITDA margin was 23.5%, including a one-time provision from changes in Indian Labour Codes; excluding this, margin was 24.8%. Profit before tax was ₹ 1,543 crores, with a 17.7% PBT margin, or 19% without the labour provision. Profit after tax attributable to equity holders was ₹ 1,210 crores, down 14% year-over-year and 16% sequentially, at 13.9% of revenues.
India revenue reached ₹ 1,603 crores, up 19% year-over-year, supported by innovation brands, new launches, price increases, higher volumes and the acquired Stugeron portfolio. The company ended the quarter with a net cash surplus of ₹ 3,069 crores and generated free cash flow of ₹ 374 crores, while preparing for Semaglutide launches and advancing biosimilar programs such as Abatacept and Denosumab.